Reunion Neuroscience reported successful Phase 2 results for its short-acting psychedelic candidate RE104 in treating postpartum depression. The drug, functionally similar to psilocybin, demonstrated symptom reduction, prompting plans to initiate a late-stage registrational trial next year. This development underscores growing interest in psychedelic-assisted therapies for neuropsychiatric indications and the potential for new approaches in maternal mental health.